Get started

Healthcare

WARNING! The biggest short seller of is “Goldman Sachs Hedge Industry VIP ETF” and I don’t know the other ones. But this one for example holds a lot of healthcare stocks (for example Change Healthcare Inc CHNG). So by buying GME some healthcare stocks, paypal, apple... etc. get at least under pressure. And a lot of stuff is invested in this etf. I couldn’t do the full research but higher prices in GME could destroy your saving on the bank or life insurances or… so nobody knows who really wins with higher prices. Maybe somebody can research that who really is losing here Please, before everything is to late. Maybe this was even on purpose to get rid of unpaid bill to the “regular” people. This ETF goes bankrupt and all the invested Money in this etf is gone! Can someone please make a full research! I wasn’t able to find it!
NYSE:GME
by spar_ma
7
MYCO - Next Move? MYCO has formed a prefect cup & handle on the daily - 4 hits against an important 0.60 resistance - handle dropped perfectly on the 0.5 fib support level - price is currently consolidating right below resistance Fundamentals in the psychedelic space are lining up perfectly for a MYCO breakout. - they are 1 in only 4 companies currently approved for phase 2 FDA trials - confirmed listing on the first ever psychedelic ETF - PSYK However, a breakout will only be confirmed after a daily close above 0.60 - volume and a newly approved catalyst will be key Good Luck to All!
CSE:MYCOLong
by LibraTradesNY
1
DNA ReconstructionAlright team i want you to keep this channel in mind as we progress through another Green Week! I am predicting this price will maintain within this channel moving forward. As you can see now it is doing a good job staying within ! Penny stocks are always volatile. However The revolutionary technology this company is bringing to the table is outstanding I am sure a lot of you already researched it and know this ! so i wont get into it. Keep in mind Buy low & NEVER SELL! Follow me for technical analysis! All of this is only opinion and my own personal journal. None of this is financial advice ! & if you dont plan on holding long term. Dont bother putting your money in this market.
NASDAQ:BNGOLong
by cortes5150
TDOC Breakout Trade, with Trigger and StopAfter the acquisition of LVGO, TDOC has traded sideways, creating a 6 month base. During that time TDOC has increased its institutional holders to 44 funds. Technically, the chart is showing an inverted head and shoulders base beakout, a trendline break, and consolidating below supply between 225-240. Above 240, TDOC can break upward to 300 with an upward target of 500. The chart is similar to ROKU's pre-breakout, which I also posted. (see related ideas). The stop would be a break below the downtrend, at 215.
NYSE:TDOCLong
by watchjoshtrade
2
$CLOV Bullish Wedge, Incoming Break Upwards$CLOV revering and nearing end of bullish wedge pattern. We likely see a nice breakup going into next week. Additionally, the Medicare Advantage Leadership Innovations meeting will be held on January 27, 2021 where they stated they'd announce a previously unannounced partnership. Recently updated 2021 provider lists notes the addition of Costco $COST. So this could be potentially huge news incoming as well as a great catalyst to retrace and retest previous high's.
NASDAQ:CLOVLong
by iamphatboy
ATRA growth potentialAtara Biotherapeutics , Inc. (Nasdaq: ATRA ), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases "Atara made significant progress in 2020 and is well-positioned for a strong 2021," said Pascal Touchon, President and Chief Executive Officer of Atara. "As the most advanced allogeneic T-cell therapy company, nearing initiation and subsequent completion of a rolling BLA for our lead product candidate tab-cel®, we are making key investments in commercial infrastructure to ensure delivery of this potentially transformative therapy to patients in dire need. Atara also anticipates significant progress throughout 2021 on ATA188 for progressive MS with multiple data read-outs and, after recent productive interactions with the FDA, is poised to expand enrollment in the RCT and conduct an interim analysis in H1 2022."
NASDAQ:ATRALong
by tsvv
Nova Leap Health Corp (NLH)Executive Summary Nova Leap Health is a consolidator of an extremely fragmented space of home care and home health care agencies. Nova Leap buys them at ~5x EBITDA and subsequently improves EBITDA margin. As the company scales its operations, the operating leverage would lead to margin expansion. The stock price has an upside of ~100% in 1 year. Opportunity 1) Small Cap (50m) 2) Sell side has not discovered it yet 3) Flying under the radar Nova presently has a $2.1m cash pile and a long term debt of $2.7m, debt was $5.3M in August with a $2.7M cash pile Business Overview NLH is home care and home health care services company operating in Vermont, New Hampshire, Massachusetts, Rhode Island, Oklahoma, Ohio, and Nova Scotia. NLH all entered into all these markets (except for Ohio) through M&A transactions. Home care covers such activities as: Dementia care Personal grooming like bathing or getting dressed Moving around: getting in and out of the bed/shower Medication reminders Errands like grocery shopping and picking up prescriptions Light housekeeping Meal preparation Home healthcare covers such activities as: Skilled nursing At-home physical therapy Pain Management Caring for wounds Prescription management Customer Value Proposition Home care and home healthcare enables senior citizens to stay in their homes even after they cannot live completely on their own. Homecare crates a buffer from when a senior citizen needs to move to a nursing facility COVID-19 Tailwind Senior citizens living at nursing facilities suffered greatly from COVID-19. There were instances where a big part of a nursing home’s population got infected by COVID-19. Second, many senior citizens got locked down at nursing facilities and were not able to see family members for very extended periods of time for safety reasons. Needless to say, that was a real hardship. Thus, I expect that both senior citizens and their families (e.g., children) would be trying to avoid or at least delay moving to a nursing facility as long as possible which would provide strong tailwinds for home care industry and Nova Leap. M&A Strategy 1. M&A Criteria Nova Leap has the following acquisition criteria: 1) U.S. and Canada geographic focus 2) Positive EBITDA with strong reputation/brand 3) Normally 5+ year history 4) Opportunities for operational synergies 5) $1M-$15M of Revenues Nova Leap is going after targets that are too small for private equity players and as a result faces limited competition. The space is very fragmented, and Nova Leap has many potential acquisition targets in front of it. M&A Playbook and Integration Nova Leap buys home care businesses that are primarily private pay. After that Nova Leap makes incremental changes at the acquired operations. First, Nova Leap implements price increases where it is appropriate. Second, Nova Leap reducea overtime because overtime destroys gross profit margin. Third, Nova Leap consolidates the back-office functions such as accounting. For example, instead of an accountant looking after one agency, such account working at Nova Leap HQ would be looking after 3 or 4 home care agencies. Fourth, better scheduling using scheduling software. Operating Philosophy CEO Chris Dobbin runs Nova Leap in a very decentralized fashion. Most locations’ leaders have lots of autonomy. HQ are responsible for setting up standards and back office / accounting. Chris Dobbin spends his time heavily on M&A and overseeing the agencies’ leaders. Unit Economics The key operating drivers are the number of client service hours and revenue per hour. Revenue per hour has been quite stable and is ~$25. Cost per hour has also been stable: ~$16.50 - $17.00. Thus, the profit per hour is ~$8.50 to $9. Four-Wall Economics and Four-Wall EBITDA “Four-wall EBITDA” is of course a misnomer because there are no tangible walls to speak of, but the concept still applies. I want to analyze profitability of field operations first and then overlay HQ expenses on top of that. The key issue that Nova Leap is facing today is its small size of field operations vs. HQ. However, with a few more acquisitions and de minimis growth in HQ expenses (see more on this below), the operating leverage would kick in and lead to a disproportionate increase in EBITDA. In 2019 segment EBITDA margin (e.g., before HQ costs) was 11.88%. However, in 1Q 2020 and 2Q 2020 it was 10.91% and 10.39% respectively due to the COVID-19 impact. Revenue run-rate (ex-COVID-19) is ~$5M per quarter or ~$20M per year. With ~12% segment EBITDA margin, NLH should be able to generate ~~$2.4M of segment EBITDA. With the EV of ~$19M, the EV/Segment EBITDA is ~7.85x. HQ Operations The HQ team based in Halifax is small and includes CEO, CFO, controller, and business development person. This is purely corporate function. The HQ also has 5 accountants. However, they work with field agencies. Nova Leap wants to do 4 to 6 M&A transactions a year (there was zero during COVID-19 pandemic so 2020 number would probably be lower than this target). Doing these M&A transactions will not require hiring any more HQ personnel. However, Nova Leap would probably need to hire an accountant for every 3-4 acquisitions (maybe 5). HQ expenses are ~$280K - $300K per quarter when there are no M&A transactions. Let’s call it $1.2M per year. Scaling What the numbers above is mean is that Nova Leap needs to get another $1M of EBITDA to show the strength of its operating model. That would probably require $5M of capital. I expect that it will be done with a very small dilution to existing shareholders. Valuation and Upside Potential As I alluded above, current headline multiple of EBITDA is not particularly attractive. However, with getting more scale and proving the model, I would not be surprised if Nova Leap trades at 12x – 14x EBIDA in 1 year could generate a 100% upside Risks M&A Integration M&A integration risks are inherent for any roll up / consolidation strategy and NLH is not exception. 2. Leverage NLH has ~$2.0M of debt which is a lot given its EBITDA today. If NLH does not grow its EBITDA, its leverage can become an issue. Catalysts 1. Continuous M&A 2. Operating leverage showing up as the company continues to scale its operations.
TSXV:NLHLong
by JabroniCapital
1
OUR VIEW ON JOB GEE GROUP INC #StockanalysisIN BUSINESS SINCE 1962, FUNDAMENTALLY, THE COMPANY SEEMS SOUND, SOURCING JOBS AND PROVING STAFFING IN THE AREAS OF HEALTHCARE, COMMERCIAL & PROFESSIONAL SERVICES. SEE MORE BELOW : GEE Group Inc. was incorporated in the State of Illinois in 1962, is a provider of specialized staffing solutions and is the successor to employment offices doing business since 1893. We operate in two industry segments, providing professional staffing services and solutions in the information technology, engineering, finance and accounting specialties and commercial staffing services through the names of General Employment, Access Data Consulting, Agile Resources, Ashley Ellis, Omni-One, Paladin Consulting and Triad. Additionally, the Company provides contract and direct hire professional staffing services through the following SNI brands: Accounting Now®, SNI Technology®, Legal Now®, SNI Financial®, Staffing Now®, SNI Energy®, and SNI Certes. Also, in the healthcare sector, through our Scribe Solutions brand, staff medical scribes who assist physicians in emergency departments of hospitals and in medical practices by providing required documentation for patient care in connection with electronic medical records. Technical Insider Own 9.20% Shs Outstand 17.75M Perf Week 30.84% Market Cap 24.96M Forward P/E - EPS next Y -0.51 Insider Trans -15.85% Shs Float 13.12M Perf Month 35.92% Income 10.10M PEG - EPS next Q -0.22 Inst Own 17.50% Short Float 0.06% Perf Quarter 38.48% Sales 129.80M P/S 0.19 EPS this Y 144.40% Inst Trans - Short Ratio 0.01 Perf Half Y 20.69% Book/sh 1.54 P/B 0.91 EPS next Y 32.90% ROA 8.20% Target Price 1.75 Perf Year 240.36% Cash/sh 0.79 P/C 1.77 EPS next 5Y - ROE 53.60% 52W Range 0.17 - 2.49 Perf YTD 40.63% Dividend - P/FCF - EPS past 5Y 20.90% ROI -2.20% 52W High -47.79% Beta 2.29 Dividend % - Quick Ratio 1.70 Sales past 5Y 24.50% Gross Margin 34.40% 52W Low 675.19% ATR 0.10 Employees 258 Current Ratio 1.70 Sales Q/Q -20.30% Oper. Margin -1.10% RSI (14) 68.16 Volatility 11.88% 8.79% Optionable No Debt/Eq 2.54 EPS Q/Q -147.00% Profit Margin 7.80% Rel Volume 3.12 Prev Close 1.40 Shortable Yes LT Debt/Eq 2.46 Earnings - Payout 0.00% Avg Volume 737.29K Price 1.30 Recom 2.00 SMA20 23.08% SMA50 26.89% SMA200 55.25% Volume 1,541,694 Change -7.14% The Content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on our Site constitutes a solicitation, recommendation, endorsement, or offer by The Trading Regime Inc. or any third party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. The Trading Regime Inc. AMEX:JOB
AMEX:JOBLong
by EvaultFinancialGroup
The $115+ NNOX Target + Patterns$NNOX is one of those volatile stocks that took the world by storm. If you don't like volatility, it is likely best to stay away from biotech or healthcare. That said, there are alot of expected catalysts. $NNOX have been heavily shortened, and it is in the opinion of many that lots of market manipulation has been and is going on. The short interest is low and the borrow rate is high. Currently as I see it, the pattern is still incrementally upwards. Nanox has the catalyst of factory announcements, FDA approvals for both single and multisource, plus the commencement of "device leasing". Currently with 4 catalyst, three of them that are expected to be big, a target of $115 seems reasonable. Support levels should be picking up soon, and unless one wants to flip for few cents or dollars per share as profit, this currently seems much better suited for a long term position. That said, I am long. Everything I say is on an opinion based basis. Please do your own due diligence and proceed with caution. Opinions mentioned here aren't meant to warrant solicited financial advice.
NASDAQ:NNOXLong
by gamer456148